Claim Missing Document
Check
Articles

Found 2 Documents
Search

PRODUCTION OF SODIUM SILICATE FROM RICE HUSK ASH WITH REGULATORY SETS MAGNESIUM pramana, yanatra budi; Pahlevi, M. Amin; Ashari, Zhulianto; Effendi, M. Fariz; Ramadhan, Fibra Gilang
Tibuana Vol 3 No 01 (2020): Tibuana Vol.3 No.1 Tahun 2020
Publisher : UNIPA PRESS

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36456/tibuana.3.01.2200.47-52

Abstract

Utilization of rice husks in Indonesia in general is still very limited. Utilization of silica contained in rice husk ash, which has been used, among others, in the manufacture of sodium silicate. Silica compounds themselves can be used in and manufacturing basic materials for electronic and ceramic equipment, glass, rubber, cosmetic products, and pharmaceuticals. The addition of Mg can increase the silica content (SiO2) in rice husk ash. The best results show an effective Mg ratio of Mg addition to increase silica content is 1: 1. produces the highest amount of silica which is 58.12% of the rice husk ash with a size of 140 mesh
ERCC2 rs13181 and ERCC1 rs11615 polymorphisms in non-small cell lung cancer patients in West Java: towards personalized medicine approaches Afifah, Nadiya Nurul; Effendi, M. Fariz; Diantini, Ajeng; Barliana, Melisa Intan; Intania, Ruri
Current Research on Biosciences and Biotechnology Vol. 6 No. 2 (2025)
Publisher : Institut Teknologi Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.5614/crbb.2025.6.2/3DCBQ451

Abstract

Non-Small Cell Lung Cancer (NSCLC) is a disease with a high incidence rate, low survival due to late diagnosis and treatment delays, and varying effectiveness of platinum-based chemotherapy. Individual responses to platinum-based chemotherapy are influenced by genetic polymorphisms in genes affecting pharmacokinetic and pharmacodynamic mechanisms. This study focuses on identifying polymorphisms in the ERCC2 and ERCC1 genes, which play a role in platinum pharmacodynamics, and their effects on chemotherapy response. The study involved 23 NSCLC patients conducted at Dr. H.A. Rotinsulu Lung Hospital in Bandung. Polymorphism data were obtained through genotype analysis using sequencing methods from prospective whole blood samples of patients, while chemotherapy effectiveness was assessed by evaluating chemotherapy response using the RECIST 1.1 method, and radiological response prediction and prognostic factors were determined through CYFRA 21-1 levels. The results showed an OR of 0.964 (95% CI: 0.160 - 5.795) for ERCC2 rs13181 CC + AC vs. AA against chemotherapy response evaluation by RECIST 1.1, and 0.722 (95% CI: 0.062 - 8.464) against CYFRA 21-1 values. Meanwhile, for ERCC1 rs11615, an OR of 0.268 (95% CI: 0.046 - 1.548) CT + TT vs. CC for RECIST 1.1 and 0.3 (95% CI: 0.026 - 3.427) for CYFRA 21-1 values were obtained. In clinical interpretation, it is known that variant alleles at rs13181 and rs11615 have potential for better chemotherapy response although not statistically significant (p>0.05), these results can be considered when assessing patient response to chemotherapy within six cycles. This study provides initial data and forms the basis for future comprehensive cohort observational research.